observation and treatment Archives - ACR Meeting Abstracts

Abstract Number: 1469 • ACR/ARHP Annual Meeting 2017
Treatment Paradigms in Real-World Practice: Biologic Agent Use Prior to and after Discontinuation of Abatacept
Rieke Alten¹, H-M Lorenz², X Mariette³, H Nüßlein⁴, M Galeazzi⁵, F Navarro⁶, M Chartier⁷, Y Elbez⁸, C Rauch⁹ and M Le Bars⁷, ¹Schlosspark-Klinik University Medicine, Berlin, Germany, ²University Hospital, Heidelberg, Germany, ³Université Paris-Sud, Paris, France, ⁴University of Erlangen-Nuremberg, Nuremberg, Germany, ⁵University of Siena, Siena, Italy, ⁶Hospital Universitario Virgen Macarena, Seville, Spain, ⁷Bristol-Myers Squibb, Rueil-Malmaison, France, ⁸Excelya, Boulogne-Billancourt, France, ⁹Bristol-Myers Squibb, Munich, Germany
Background/Purpose: ACTION is a 2-year, observational study of patients (pts) with moderate-to-severe RA who initiated IV abatacept in Canada and Europe (NCT02109666). The objective was…
Abstract Number: 2253 • ACR/ARHP Annual Meeting 2016
Treatment Persistence with Subcutaneous TNF-Alpha Inhibitors in France
Manon Belhassen¹, Christophe Hudry², Marie-Christine Woronoff³, Liliane Lamezec⁴, Najat Gouyette⁴, Marine Ginoux¹, Eric Van Ganse¹, Florence Tubach⁵ and Bruno Fautrel⁶, ¹PELyon, Pharmacoepidemiologie Lyon, France, Lyon, France, ²AP-HP Hôpital Cochin, Paris, France, ³INSERM-U-1098, DRCI-CHRU Besançon, Franche-Comté University, UBFC, Besançon France, Besançon, France, ⁴MSD France, Courbevoie, France, ⁵Université Pierre et Marie Curie (UPMC)-Paris 6; APHP, Pitié Salpêtrière Hospital, Département Biostatistics and Public health, Pharmacoepidémiology center (Cephepi), 7501875013, Paris, France ;, Paris, France, ⁶Rheumatology, Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: Immune-mediated rheumatic disease (IMRD) including rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS), are severe and disabling chronic diseases in rheumatology. Biotherapies…

Abstracts tagged "observation and treatment"

Treatment Paradigms in Real-World Practice: Biologic Agent Use Prior to and after Discontinuation of Abatacept

Treatment Persistence with Subcutaneous TNF-Alpha Inhibitors in France